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Melioidosis is an infectious disease with a propensity for relapse, despite prolonged antibiotic eradication therapy
for 12 to 20 weeks. A pharmacokinetic (PK) simulation study was performed to determine the optimal dosing of
cotrimoxazole (trimethoprim-sulfamethoxazole [TMP-SMX]) used in current eradication regimens in Thailand
and Australia. Data for bioavailability, protein binding, and coefficients of absorption and elimination were taken
from published literature. Apparent volumes of distribution were correlated with body mass and were estimated
separately for Thai and Australian populations. In vitro experiments demonstrated concentration-dependent kill-
ing. In Australia, the currently used eradication regimen (320 [TMP]/1,600 [SMX] mg every 12 h [q12h]) was
predicted to achieve the PK-pharmacodynamic (PD) target (an area under the concentration-time curve from 0 to
24 h/MIC ratio of >25 for both TMP and SMX) for strains with the MIC90 of Australian strains (<1/19 mg/liter).
In Thailand, the former regimen of 160/800 mg q12h would not be expected to attain the target for strains with an
MIC of >1/19 mg/liter, but the recently implemented weight-based regimen (<40 kg [body weight], 160/800 mg
q12h; 40 to 60 kg, 240/1,200 mg q12h; >60 kg, 320/1,600 mg q12h) would be expected to achieve adequate
concentrations for strains with an MIC of <1/19 mg/liter. The results were sensitive to the variance of the PK
parameters. Prospective PK-PD studies of Asian populations are needed to optimize TMP-SMX dosing in
melioidosis.
Melioidosis, a serious human infectious disease caused by
the gram-negative bacterium Burkholderia pseudomallei, is en-
demic in northern Australia and southeast Asia. The in-hospi-
tal mortality rate averages 20% in Australia and 40 to 50% in
northeast Thailand. In survivors of acute disease, recurrence
after apparent clinical response, despite appropriate antibiotic
treatment, is reported at rates of between 13 and 23% (5, 9).
Molecular typing has determined that the majority (75%) of
recurrent disease is due to persistence and subsequent relapse
of the original infecting strain, with 25% of cases being second
infections (17). Current antibiotic recommendations are for an
intensive intravenous phase (ceftazidime or a carbapenem) for
10 to 14 days followed by a prolonged eradication phase (tri-
methoprim-sulfamethoxazole [TMP-SMX], or cotrimoxazole,
alone or in combination with doxycycline) (6).
Dosing regimens for the eradication phase of treatment vary
between countries. In Australia, a TMP-SMX dose of 320/
1,600 mg (two double-strength tablets) every 12 h (q12h) is
recommended. In Ubon Ratchathani, Thailand, a TMP-SMX
dose of 160/800 mg (two single-strength tablets) q12h (with
doxycycline) has been used previously. However, a new weight-
based dosing protocol (for patients of 40 kg [body weight],
160/800 mg q12h; 40 to 60 kg, 240/1,200 mg q12h; and 60 kg,
320/1,600 mg q12h, plus doxycycline) is now used.
TMP-SMX is a commonly used synergistic antibiotic com-
bination that acts on successive enzymes in the bacterial folate
synthesis pathway. The appropriate pharmacokinetic-pharma-
codynamic (PK-PD) parameter has not been defined for TMP-
SMX. Limited data from children with pneumococcal otitis
media suggested that clinical efficacy correlates with the pro-
portion of time when antibiotic concentrations exceed the MIC
of the infecting organism (8).
In this study, we performed time-kill studies to assess the
likely PK-PD target and evaluated the TMP-SMX dosing reg-
imens using a simulation model with Thai and Australian pop-
ulations.
MATERIALS AND METHODS
Time-kill studies. We performed time-kill studies using three Thai clinical
isolates (strains 4861a [MIC, 4 g/ml], 3126a [MIC, 1 g/ml], and 3131a [MIC,
0.25 g/ml]). These were identified as B. pseudomallei by the use of standard
methods, and the MIC was determined by Etest. Time-kill studies were per-
formed in duplicate in 30-ml bottles containing 10 ml of Mueller-Hinton broth
(Oxoid, United Kingdom). A logarithmic-phase broth culture was diluted to give
a starting inoculum of approximately 1  106 CFU/ml. Bottles were then incu-
bated in a rotary shaker at 37°C in air with various concentrations of TMP-SMX
corresponding to the MIC, 4 times the MIC, 6 times the MIC, and 10 times the
MIC. Antibiotic-free broth was included as a control. Viability counts of an
aliquot diluted in antibiotic-free broth were performed at 0, 4, 8, and 24 h and
plotted on a logarithmic scale against time. Additional studies were performed
using concentrations of 10 times, 20 times, and 40 times the MIC at 0, 15, 30, 45,
and 60 min. Statistical analyses were performed on log-transformed data.
PK parameters. We used a single-compartment PK model with probabilistic
sampled parameters for TMP and SMX separately. We considered regional
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variation in the MIC90 (the MIC required to inhibit the growth of 90% of
bacterial isolates) and body weight and derived other PK parameters (including
the coefficients of absorption and elimination, plasma protein binding, and bio-
availability) from published literature. We considered four dosing regimens for
TMP and SMX: 160/800 mg q12h, 160/800 mg q8h, 320/1,600 mg q12h, and
320/1,600 mg q8h. We also evaluated the weight-based protocol (40 kg, 160/800
mg q12h; 40 to 60 kg, 240/1,200 mg q12h; and 60 kg, 320/1,600 mg q12h).
In a published series, the PK variables associated with TMP and SMX are
reported as means and standard deviations, suggesting that they are normally
distributed (Table 1). Volume of distribution correlated with body mass. Volume
of distribution/body mass was estimated from PK studies (performed mainly with
European populations) and data from the 1995 United Kingdom Health Survey
(13). For simulations involving Thai patients, published data on variation in body
mass in Khon Kaen, northeast Thailand, were used in estimating parameters
(21). For simulations involving Australian patients, published data were obtained
from the 1995 Australian National Nutrition Survey (1).
PD parameters. On the basis of time-kill studies demonstrating concentration-
dependent killing, we defined the PK-PD target as 24-h drug exposure (free area
under the concentration-time curve from 0 to 24 h [fAUC0–24 h]/MIC ratio of
25) in our analysis. We also assessed the dosing regimens against an alternative
target in which TMP-SMX free-blood concentrations exceeded the MIC90 for at
least 60% of the interdose period based on previous work with pneumococcal
disease (8). The TMP-SMX MIC90 demonstrates geographic variation. Deter-
mination of the MIC (by Etest) of 80 Queensland isolates (20) and 170 clinical
isolates from the Northern Territory (14) found that the MIC90 was 1/19 mg/liter,
with only three isolates in the latter study having an MIC of 2/38 mg/liter.
However, in Thailand, the MIC90 for 1,976 clinical isolates was 3/58 mg/liter by
the Etest (30). We used primary data on the MIC from Thailand to determine
the proportion of isolates for which concentrations of TMP-SMX were expected
to be adequate. We performed two sensitivity analyses, the first assuming that PK
parameters varied in a log-normal, rather than a normal, distribution and the
second doubling the coefficient of variation in PK parameters to account for
possible variation due to disease states.
Simulation. PK formulae (Appendix) were programmed using MATLAB 7.1
(Mathworks, Natick, MA). All parameters contributing to the PK formulae were
assumed to be independent, normally distributed random variables (or log-
normal in the sensitivity analysis). A Monte Carlo integration method was used
to determine the expected range of serum antibiotic concentrations over a 24-h
dosing interval across each population. Values for each of the parameters were
sampled from their distributions, and the expected serum concentrations over a
24-h period were calculated. The fAUC0–24 h/MIC ratio and the proportion of
time over the MIC90 for each region were derived by integration. Ten thousand
simulations were conducted, and the proportion of the population expected to
achieve the PK-PD target was noted for each simulation. A sensitivity analysis
examined the probability of attainment of an alternative target, a concentration
exceeding the MIC for at least 60% of the interdose period.
RESULTS
Time-kill studies. Bacterial concentrations were similar in
all groups at time zero (analysis of variance, P 0.47) but were
different between the relative concentrations of TMP-SMX at
4 h, 8 h, and 24 h of incubation (all P  0.001; Table 2). This
suggests concentration-dependent killing between 0 and 4 h
and a bacteriostatic effect between 4 and 24 h (Fig. 1). At
higher concentrations, there was complete killing at 30 min
FIG. 1. Log bacterial concentrations over time in strains 4861a,
3126a, and 3131a incubated with various concentrations of TMP-SMX
relative to the strain MIC. Bars represent geometric mean and stan-
dard deviation of bacterial concentration (CFU/ml) of the three strains
in assays performed in duplicate.
TABLE 1. Pharmacokinetic parameters used in this studyc
Parameter
TMP SMX
Value(s) Reference(s) Value(s) Reference(s)
Bioavailability (F) 0.875 ( 0.064) 15, 18, 23, 25 0.95 ( 0.026) 15, 23, 25
Coefficient of absorption (ka)
a 1.63 ( 0.50) h1 15, 18, 23–25, 29 1.13 ( 0.24) h1 18, 23–25
Coefficient of elimination (ke)
b 0.080 ( 0.010) h1 15, 18, 23, 25, 29 0.080 ( 0.0054) h1 15, 23, 25, 29
Vol of distribution (Vd) 110 liter (1.46 liter/kg) 13, 18, 19, 23, 25, 29 16 liter (0.213 liter/kg) 13, 19, 23, 25, 29
Binding to plasma proteins 50.0  1.7% 27 60.2  3.7% 27
Thai adult body mass 60.0 ( 10.2) kg 21 60.0 ( 10.2) kg 21
Estimated vol of distribution
in Thai adults
88 ( 14.8) liter 12.8 ( 2.2) liter
Australian adult body mass 80.0 ( 14.5) kg 1 80.0 ( 14.5) kg 1
Estimated vol of distribution
in Australian adults
116 ( 21.4) liter 17 ( 3.1) liter
a Calculated from time to peak concentration and terminal half-life, where not reported directly.
b Calculated from terminal half-life, where not reported directly.
c In primary analysis, parameters were assumed to follow normal distribution, with mean and standard deviation shown.
TABLE 2. Log bacterial concentrations over time in strains 4861a,
3126a, and 3131a incubated with various concentrations of
TMP-SMX relative to the strain MICa
TMP-SMX
concn
Bacterial concn (CFU/ml)
Baseline 4 h 8 h 24 h
Control 6.01  0.047 7.55  0.32 8.48  0.47 10.07  0.84
1 MIC 6.08  0.066 5.76  0.39 6.57  0.59 7.33  1.09
4 MIC 6.04  0.11 5.29  0.43 5.20  0.88 5.24  1.76
6 MIC 6.03  0.046 5.12  0.42 5.23  0.51 4.57  1.72
10 MIC 6.08  0.084 3.62  0.20 3.66  0.037 3.30  1.16
a Results represent geometric mean and standard deviation of bacterial con-
centrations of the three strains in studies performed in duplicate.
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following incubation with TMP-SMX at 20 times the MIC and
at 15 min following incubation with 40 times the MIC. In a
log-linear regression model, increasing the TMP-SMX concen-
tration was associated with a decreasing bacterial concentra-
tion, after adjusting for the duration of incubation (coefficient
of 0.33 log, P  0.001).
PK-PD target of an AUC0–24 h/MIC ratio of >25. For Thai
adults, TMP dosing of at least 160 mg q8h was required before
the probability of PK-PD target attainment exceeded 80%, if
infecting isolates had an MIC of 1 mg/liter. The PK-PD target
could be achieved reliably only with high TMP dosing (320 mg
three times a day) at the susceptibility breakpoint (2 mg/liter)
and could not be achieved for any dosing regimen with a high
probability for the MIC90 (3 mg/liter) in this region (Table 3).
For SMX, dosing regimens of 800 mg q8h or greater achieved
adequate concentrations exceeding the susceptibility threshold
(38 mg/liter), and 1,600-mg-q12h dosing achieved adequate
concentrations exceeding the MIC90 (57 mg/liter) in the region
(Table 3). The Thai weight-based protocol would be expected
to achieve the PK-PD target for strains with an MIC of up to
1/19 mg/liter. Based on the distribution of the TMP-SMX MIC
observed in a previous study (30), the weight-based protocol
would be expected to achieve an AUC0-24 h/MIC ratio of 25
with 82% of Thai patients.
For Australian adults, a TMP dose of 320 mg q12h had an
81% probability of achieving target attainment for isolates at
the MIC90 of the region (1 mg/liter), and the weight-based
protocol was predicted to have a high probability of achieving
the target AUC/MIC ratio. No regimen could reliably achieve
concentrations adequate to exceed the susceptibility threshold
(2 mg/liter) (Table 4). All SMX dosing regimens achieved
adequate concentrations exceeding the regional MIC90 (19
mg/liter), and SMX dosing regimens of 1,600 mg q12h or
higher achieved adequate concentrations exceeding the sus-
ceptibility threshold (38 mg/liter).
Sensitivity analyses. With Australian adults, the probability
of attainment of the AUC/MIC ratio target for the TMP-SMX
320-/1,600-mg regimen at the Australian MIC90 threshold of
1/19 mg/liter was reduced from 81% to 71%, assuming a higher
variance in PK parameters (bioavailability, coefficients of ab-
sorption and elimination, and protein binding). The propor-
tion of patients achieving the target AUC/MIC ratio remained
high (97%), assuming higher variance in PK parameters. The
probability of target attainment for strains with an MIC of 1/19
mg/liter was not significantly different (84%), assuming a log-
normal distribution of PK parameters.
In Thai adults, the probability of attainment of the target
AUC/MIC ratio of the 160-/800-mg-q8h regimen for strains
with an MIC of 1/19 mg/liter was reduced to 72% if a higher
variation in PK parameters was assumed. Both the 320-/1,600-
mg-q12h and weight-based regimens reliably attained the tar-
get AUC/MIC ratio for isolates with an MIC of 1/19 mg/liter,
assuming higher variation in PK parameters (1,600 mg twice
daily, 94%; and weight-based, 87%). The probability of target
attainment for strains with an MIC of 1/19 mg/liter was not
changed significantly, assuming a log-normal distribution of
PK parameters.
PK-PD target concentrations higher than MIC for >60% of
interdose period. In Thai adults, the TMP 320-mg-q12h regimen
would be required to reliably achieve concentrations exceeding
the MIC for 60% of the interdose period for isolates with an
MIC up to 1 mg/liter (Table 5; Fig. 2). SMX dosing regimens of
800 mg q8h were adequate for susceptible strains (Table 5). The
weight-based protocol was expected to attain the PK-PD target
with 93% of Thai patients infected with a strain with an MIC of
1 mg/liter but with only 1.5% of patients infected with isolates at
the susceptibility breakpoint (2 mg/liter). Based on the distribu-
tion of the TMP MIC from a previous study (30), the weight-
based protocol would be expected to achieve TMP-SMX concen-
trations exceeding the MIC for at least 60% of the interdose
interval with 81% of patients.
TABLE 3. Predicted probability of target attainment (AUC0–24h/
MIC ratio of 25) with Thai population
Dosing regimend
Breakpoint (%) Proportion with
adequate
concentrations (%)
1/19
mg/litera
2/38
mg/literb
3/57
mg/literc
TMP
160 mg q12h 18 0.1 0.1 44
160 mg q8h 80 2 0.1 61
320 mg q12h 99 17 0.1 72
320 mg q8h 100 81 18 85
Weight based 100 59 2 82
SMX
800 mg q12h 100 39 1.8 80
800 mg q8h 100 99 34 90
1,600 mg q12h 100 100 92 94
1,600 mg q8h 100 100 100 96
Weight based 100 100 100 95
a 1 (TMP)/19 (SMX) mg/liter represents the MIC90 for Australian isolates.
b 2/38 mg/liter represents the susceptibility threshold.
c 3/57 mg/liter represents the MIC90 for Thai isolates.
d Weight-based dosing for patients was as follows: 40 kg (body weight),
160/800 mg q12h; 40 to 60 kg, 240/1,200 mg q12h; and 60 kg, 320/1,600 mg
q12h.
TABLE 4. Predicted probability of target attainment (AUC0–24h/
MIC ratio of 25) with Australian patients
Dosing regimend
Breakpoint (%)
1/19
mg/litera
2/38
mg/literb
3/57
mg/literc
TMP
160 mg q12h 3 0.1 0.1
160 mg q8h 36 0.2 0.1
320 mg q12h 81 3 0.2
320 mg q8h 100 36 3
Weight based 100 31 0.6
SMX
800 mg q12h 98 7 0.2
800 mg q8h 100 66 7
1,600 mg q12h 100 98 42
1,600 mg q8h 100 100 98
Weight based 100 100 98
a 1 (TMP)/19 (SMX) mg/liter represents the MIC90 for Australian isolates.
b 2/38 mg/liter represents the susceptibility threshold.
c 3/57 mg/liter represents the MIC90 for Thai isolates.
d Weight-based dosing for patients was as follows: 40 kg (body weight),
160/800 mg q12h; 40 to 60 kg, 240/1,200 mg q12h; and 60 kg, 320/1,600 mg
q12h.
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With Australian adults, TMP dosing of 320 mg q12h would
be expected to be adequate to achieve the PK-PD target with
73% of patients infected with isolates at the regional MIC90
(1 mg/liter). No TMP dosing regimen was able to reliably
achieve the PK-PD target for isolates at the susceptibility
breakpoint (Table 6; Fig. 3). SMX dosing at 800 mg q12h
would be expected to be adequate for strains with the MIC90 (1
mg/liter), but 800 mg q8h or higher would be associated with a
high probability of target attainment.
DISCUSSION
Despite prolonged eradication treatment courses, melioidosis
is still associated with a significant relapse rate. In this study, we
attempt to define an optimal dosing regimen of TMP-SMX that
may reduce relapse. Limited data had suggested that for antibi-
otics with a time-dependent action (such as beta-lactams and
TMP-SMX), improvements in clinical outcomes plateau when
the time period in which the concentration exceeds the MIC90 is
more than 60% (8). However, our data suggest that TMP-SMX
exerts a concentration-dependent killing effect on B. pseudomallei
within the blood concentration range achievable in vivo.
The assessment of TMP-SMX susceptibility is problematic.
FIG. 2. Predicted concentration-time graphs for Thai adults.
TABLE 5. Predicted probability of target attainment (concentration
exceeding MIC for 60% of interdosing interval)
in Thai patients
Dosing regimend
Breakpoint (%) Proportion with
adequate
concentrations (%)
1/19
mg/litera
2/38
mg/literb
3/57
mg/literc
TMP
160 mg q12h 13 0.1 0.1 57
160 mg q8h 79 2 0.1 70
320 mg q12h 98 13 0.1 85
320 mg q8h 100 79 17 97
Weight based 100 93 25 91
SMX
800 mg q12h 100 31 1 88
800 mg q8h 100 99 40 93
1,600 mg q12h 100 100 86 96
1,600 mg q8h 100 100 100 97
Weight based 100 100 100 97
a 1 (TMP)/19 (SMX) mg/liter represents the MIC90 for Australian isolates.
b 2/38 mg/liter represents the susceptibility threshold.
c 3/57 mg/liter represents the MIC90 for Thai isolates.
d Weight-based dosing for patients was as follows: 40 kg (body weight),
160/800 mg q12h; 40 to 60 kg, 240/1,200 mg q12h; and 60 kg, 320/1,600 mg
q12h.
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One study has suggested that TMP-SMX exerts a bactericidal
action (2), but another suggests that it is bacteriostatic (11).
Susceptibility testing for TMP-SMX has been difficult, with
disc diffusion proving unreliable and MIC testing proving un-
reliable because of unclear end points (20, 30). Assessment of
the TMP-SMX MIC using the Etest method has demonstrated
lower susceptibility of B. pseudomallei isolates from Thailand
than of those from Australia, with 38% of clinical isolates
having an MIC of 1/19 mg/liter and 13% having an MIC of
2/38 mg/liter (30). In contrast, only 3 of 170 strains had an
MIC of 1/19 mg/liter in one Australian study (14).
This study suggests that in Thailand, dosing regimens of
TMP-SMX may be inadequate for strains at or around the
susceptibility threshold. Susceptibility testing using the Etest
provides more reliable end points and has recently been
adopted by many major centers in northeast Thailand. This
simulation study suggests that the new weight-based protocol
(or a regimen of 320/1,600 mg twice daily) would be expected
to achieve adequate serum exposure of TMP and SMX relative
to the MICs of susceptible strains. In Australia, the currently
used regimen of cotrimoxazole, 320/1,600 mg (two double-
strength tablets) q12h, should be adequate for local isolates
with an MIC of 1/19 mg/liter.
FIG. 3. Predicted concentration-time graphs for Australian adults.
TABLE 6. Predicted probability of target attainment (concentration
exceeding MIC for 60% of interdosing interval)
with Australian patients
Dosing regimen
Breakpoint
1/19
mg/litera
2/38
mg/literb
3/57
mg/literc
TMP
160 mg q12h 2 0.1 0.1
160 mg q8h 35 0.2 0.1
320 mg q12h 72 3 0.1
320 mg q8h 100 35 3
Weight based 100 29 0.7
SMX
800 mg q12h 96 5 0.2
800 mg q8h 100 66 7
1,600 mg q12h 100 96 34
1,600 mg q8h 100 100 98
Weight based 100 100 98
a 1 (TMP)/19 (SMX) mg/liter represents the MIC90 for Australian isolates.
b 2/38 mg/liter represents the susceptibility threshold.
c 3/57 mg/liter represents the MIC90 for Thai isolates.
d Weight-based dosing for patients was as follows: 40 kg, 160/800 mg q12h;
40 to 60 kg, 240/1,200 mg q12h; and 60 kg, 320/1,600 mg q12h.
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A previous study examined the dosing of coamoxiclav, sug-
gesting that very-frequent-dosing regimens (six hourly or more
frequent) are required to achieve adequate concentrations of
these beta-lactams, based on checkerboard testing of clinical
isolates (7). Inadequate dosing, as well as poorer tolerance and
compliance, may explain why current dosing of coamoxiclav is
associated with a relapse rate higher than those of TMP-SMX-
based regimens in Thailand (16, 22). Similarly, the four-drug
regimen of TMP-SMX, doxycycline, and chloramphenicol has
been found to be antagonistic in vitro and poorly tolerated in
vivo compared to TMP-SMX and doxycycline (3, 12). In Aus-
tralia, TMP-SMX has been used alone, with few relapses doc-
umented (10). A trial of eradication therapy has recently
started in Thailand using the weight-based dosing regimen of
TMP-SMX (versus TMP-SMX and doxycycline).
Higher recurrence rates were documented in Thailand than
in Australia before the recent implementation of the weight-
based dosing regimen (5, 9). Possible explanations for this
include the use of multiple (and possibly antagonistic) drug
combinations (12), the higher rate of reinfection (rather than
relapse) documented (17), and poor compliance rates (3, 4,
22). This study suggests that the previous dosing of TMP-SMX
may have been suboptimal and may have been a contributing
factor, explaining this regional difference in relapse rates. This
study also has implications for laboratories in which TMP-
SMX is used in postexposure prophylaxis following accidental
exposure.
There are several limitations of this study. The apparent
volumes of distribution used in the PK simulations were de-
rived from anthropomorphic studies in each region, rather
than the patients treated. To our knowledge, PK studies of
TMP-SMX have not been performed with Asian populations.
Other studies have defined important factors associated with
relapse of melioidosis, such as tolerability and compliance, and
higher doses of TMP-SMX may be associated with gastroin-
testinal and hematological intolerance. We used a simple one-
compartment model; the site of persistence and the focus of
later relapse for B. pseudomallei are not known, and the con-
centrations and TMP/SMX ratios in these compartments may
be important. Some studies have demonstrated that B.
pseudomallei in biofilm has an MIC 200 times higher than that
of planktonic cells of B. pseudomallei; the clinical significance
of this is not yet known (28). We did not use checkerboard
testing in this study, as previous studies have defined the op-
timal ratio of TMP/SMX as 1:20, as used in susceptibility
testing, and there is considerable uncertainty in defining the
actual ratio at the site of action (23). Finally, no data on the
appropriate PK-PD target are available from clinical studies,
and our choice of a target AUC/MIC ratio of 25 is arbitrary.
Renal disease is common in patients with melioidosis; in
addition to acute renal impairment related to sepsis, risk fac-
tors for melioidosis include diabetes mellitus (present in over
half the patients with melioidosis) and nephrolithiasis second-
ary to renal tubular acidosis (26). Reduced renal clearance of
TMP-SMX results in higher accumulation, and a dose reduc-
tion may be required. We did not model the effect of renal
disease in this study. Although acute sepsis is usually asso-
ciated with an increased variability in PK parameters, in
melioidosis, TMP-SMX is used primarily for eradication
therapy following treatment of acute disease with intrave-
nous ceftazidime. However, the results of the simulation
were sensitive to the variance in PK parameters, highlight-
ing this as an issue in future PK-PD studies.
In this study, we have demonstrated that TMP-SMX is as-
sociated with concentration-dependent killing effects. Simula-
tion suggests that the dosing regimen previously used in Thai-
land may not be sufficient for strains at or above the
susceptibility threshold. In addition to other factors, including
compliance with and the tolerability of the prolonged course of
eradication therapy, the high MIC found in Thailand com-
pared to Australia, and the higher reinfection rate, TMP-SMX
dosing may account for the higher relapse rate documented in
Thailand. The current weight-based regimen is predicted to
achieve adequate concentrations of TMP and SMX. Studies
are needed to verify the pharmacokinetics of TMP-SMX in
Thai populations, to determine the tolerability of higher doses
of TMP-SMX, and to validate the correlation between phar-
macokinetics and clinical outcome in melioidosis.
APPENDIX
The coefficient of elimination, ke, is calculated from the terminal
half-life, t1/2, by the formula:
ke
ln	2

t1/2
(1)
The time to maximum concentration, Tmax, is given by the following
expression; the coefficient of absorption, ka, can be found numerically.
Tmax
ln	ka/ke

ka ke
(2)
For multiple dosing, the total concentration, C, at time t is given by
the following expression, where repeated doses, D, with bioavailability
F are administered every  hours.
Ct
FDka
Vd	ka ke

 eket	1 ek
 e
kat
	1 eka (3)
The free, or unbound, concentration of drug, Cf, is calculated
from the total drug concentration, Ct, and protein binding, B, as
follows: Cf  B  Ct.
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